Over the years extensive work has gone into developing selective antagonists targeting P2Y2 for the purpose of preventing tumor metastasis, skin fibrosis, cystic fibrosis, inflammation, and atherosclerosis (Burnstock 2017). This evidence concerns the gene P2RY2 and atherosclerosis.